Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 3, 2025 • 9:01 PM ET

Date/Time Source News Release
12/18/2024 08:00 AM EST Business Wire Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
12/12/2024 08:00 AM EST Business Wire Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
11/19/2024 08:00 AM EST Business Wire Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice
10/16/2024 08:00 AM EDT Business Wire Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's
10/15/2024 08:00 AM EDT Business Wire Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
10/10/2024 08:00 AM EDT Business Wire Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group's Virtual Healthcare Conference
08/26/2024 08:00 AM EDT Business Wire Alzamend Neuro Issues Letter to Stockholders
08/19/2024 08:00 AM EDT Business Wire Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next?Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
08/12/2024 08:00 AM EDT Business Wire Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next?Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder 
08/06/2024 08:00 AM EDT Business Wire Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next?Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
Page

Additional News

As of January 3, 2025 • 9:01 PM ET

Date/Time Source News Release
12/12/2024 08:06 AM EST SeekingAlpha Alzamend Neuro GAAP EPS of -$0.40 beats by $0.37
10/15/2024 08:13 AM EDT SeekingAlpha Alzamend Neuro regains compliance with Nasdaq
09/11/2024 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Wednesday, September 11th, 2024
09/11/2024 05:33 AM EDT US Earnings Reports Expected earnings - Alzamend Neuro Inc.
08/20/2024 04:30 PM EDT QM US Market Movers News US Companies Moving the Markets, Evening edition
Tue, Aug 20, 2024 as of 4:00 pm ET
08/19/2024 10:00 AM EDT QM US Market Movers News US Companies Moving the Markets, Morning edition
Mon, Aug 19, 2024 as of 10.00 am ET
08/01/2024 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Thursday, August 1st, 2024
08/01/2024 05:33 AM EDT US Earnings Reports Expected earnings - Alzamend Neuro Inc.
07/25/2024 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Thursday, July 25th, 2024
07/25/2024 05:32 AM EDT US Earnings Reports Expected earnings - Alzamend Neuro Inc.
Page